Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain

Autor: María-Eva Mingot-Castellano, Carlos Grande-García, David Valcárcel-Ferreiras, Clara Conill-Cortés, Loreto de Olivar-Oliver

Publikováno v: Case Reports in Hematology, Vol 2017 (2017)

Romiplostim, a thrombopoietin-receptor agonist (TPO-ra), is a highly effective option in primary immune thrombocytopenia (ITP), with 80–90% of patients achieving platelet responses after few weeks of treatment. The evidence showing remissions, that

Externí odkaz: https://doaj.org/article/4dddb6c22ad743c3a567ef280b6c2498

IBRORS-LCM: A SPANISH RETROSPECTIVE, OBSERVATIONAL, RETROSPECTIVE STUDY OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) TREATED WITH IBRUTINIB IN ROUTINE CLINICAL PRACTICE

Autor: Sancho, Juan-Manuel, Marin, Ana, Fernandez, Silvia, Capote, Francisco-Javier, Canigral, Carolina, Carlos Grande García, Donato, Eva, Zeberio, Izaskun, Puerta, Jose-Manuel, Rivas, Alfredo, Perez-Ceballos, Elena, Vale, Ana, Jimenez, Aroa, Loriente, Cristina

Publikováno v: Haematologica
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
r-FISABIO. Repositorio Institucional de Producción Científica
Web of Science

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::406f4629054b9586bcef803c392de46a
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3971

Erratum

Autor: Carlos Grande García

Publikováno v: Annals of Allergy, Asthma & Immunology. 119:298

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d1eca4ecc8cf8671c1032324c73f53
https://doi.org/10.1016/j.anai.2017.07.018

Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients

Autor: Ana Jiménez Ubieto, Andrea Galego, Luis Palomera, Marina Manzanares, Erika Coria, Silvana Novelli, Lucrecia Yáñez, Elena Pérez, Santiago Mercadal, Teresa Palomo, Laura Magnano, Dolores Caballero, Carlos Vallejo, Pilar Martinez Sanchez, Maria J. Rodriguez, Isidro Jarque, Juan José Lahuerta, Carmen Albo, Carlos Grande García, Armando López-Guillermo, Javier Lopez Jimenez, Reyes Arranz, Antonio Salar, Sabela Bobillo, Carmen Marrero, José Javier Ferreiro

Publikováno v: Blood. 126:521-521

Introduction: At present, determining OS (Overall Survival) remains the gold standard in clinical trial endpoints which evaluate the role of ASCT in FL. However, in the context of a disease characterized by very long median survivals with a continuou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d1588d93ce14e3783cded6c1d1a1b8d
https://doi.org/10.1182/blood.v126.23.521.521

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Autor: Franck Morschhauser, Eva González Barca, Andrew Saunders, Catherine Thieblemont, Karen Dwyer, Francesco d'Amore, Martine E.D. Chamuleau, John Radford, Dolores Caballero, Carlos Grande García, Pier Luigi Zinzani, Bertrand Coiffier, Paul Fields, Corinne Haioun, Gustaaf W. van Imhoff, Peter Johnson

Publikováno v: Blood. 124:1763-1763

Background CC chemokine receptor 4 (CCR4) is the receptor for macrophage-derived chemokine (MDC/CCL22) and thymus activation-regulated chemokine (TARC/CCL17). CCR4 is expressed on tumour cells in approximately 30-65% of patients with PTCL (Ogura, 201

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::19ed9935ba1d60dd3aae2bde488851a6
https://doi.org/10.1182/blood.v124.21.1763.1763